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The UK Food Standards Agency convened a group of expert scientists to review current research investigating folate and colo-rectal cancer risk.
The workshop aimed to examine current research and establish research priorities. The timing of folate exposure with respect to carcinogenesis, as
well as the dose and form of folate, were considered key issues for future research. Also, the need to study further the influence of genetically
defined subgroups was highlighted for future research.
Colo-rectal cancer: Folate: Folic acid: Food Standards Agency
The UK Food Standards Agency (FSA) convened a workshop
on 29 November 2006, on folate and colo-rectal cancer (CRC)
risk. The results from recently completed studies, both FSA
and non-FSA funded, were presented. The workshop was
chaired by Professor John Baron.
Background
Folate is a generic term for a B-group vitamin (vitamin B9)
found widely in foodstuffs. Folic acid (pteroylmonoglutamic
acid) is the synthetic form used in supplements and food for-
tification. Folates function coenzymatically in the transfer and
processing of one-carbon units and play an important role in
nucleotide synthesis, methylation, and the regulation of gene
expression.
A meta-analysis of prospective cohort and case–control
studies1 concluded that folate has a modest inverse association
with risk of CRC, although confounding by other dietary fac-
tors could not be ruled out. The inverse association observed
was stronger for dietary folate than total folate (food and sup-
plemental folate) intakes. Of the prospective cohort studies
published since the meta-analysis, one has observed an inverse
association between dietary folate intake and colon cancer
risk2, which was more pronounced among smokers, while,
in contrast, a nested case–control study observed a bell-
shaped association between plasma folate concentration and
CRC risk; subjects with a plasma folate in the lowest concen-
tration quintile had a lower CRC risk3. One other prospective
study observed dietary folate not to be associated with the risk
of CRC, but that intake of folate (and vitamin B6) were inver-
sely associated with risk among women not taking sup-
plements4.
In general, prospective cohort studies of an association
between folate and colo-rectal adenoma risk provide some
support for a role of folate in modulating colo-rectal carcino-
genesis5–7.
Methylenetetrahydrofolate reductase is a key enzyme regu-
lating folate metabolism. Homozygotes (TT) for the MTHFR
677C . T gene polymorphism have been associated with a
moderately reduced CRC risk8, particularly among individuals
who are folate-replete. Results from studies of the association
between MTHFR 677C . T and risk of adenomatous polyps
are inconsistent.
Overall the epidemiological evidence is suggestive of a
modest inverse association between dietary folate and CRC
risk, but confounding by other dietary factors may be a
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factor9. Polymorphisms in folate-metabolizing enzymes may
also modify CRC risk in relation to folate intake.
Folate: a magic bullet or a double-edged sword for colo-
rectal cancer prevention?
Professor Young-In Kim presented the evidence from animal
studies investigating the role of folate in colo-rectal carcino-
genesis. Studies using chemical colon carcinogens in rodent
models have shown that a moderate degree of folate deficiency
promotes, whereas modest levels of folic acid supplementation
up to four times the basal daily requirement inhibits the devel-
opment of CRC10,11. In contrast, folic acid supplementation
exceeding the basal daily requirement by 20 to 10,000 times
enhanced colo-rectal carcinogenesis in the chemical carcino-
gen rodent model of CRC12–15.
In a genetically engineered murine model of CRC, the
ApcMin mouse, both semi-synthetic diets that contained one-
third and twice the basal daily requirement for folic acid,
respectively, increased the number of small intestinal
polyps16. In the ApcMin and ApcMin £ Msh22/2 mouse
models, moderate dietary folate deficiency enhanced, whereas
modest levels of folic acid supplementation (four- to ten-times
basal daily requirement) suppressed the development and pro-
gression of CRC, if folate intervention was started before the
establishment of neoplastic foci in the intestine17,18. If, how-
ever, folate intervention was started after the establishment
of neoplastic foci, the same degree of folate deficiency inhib-
ited the progression and induced regression of the established
neoplastic foci17,18. Furthermore, a potential tumour-promot-
ing effect of folic acid supplementation on established neo-
plastic foci (aberrant crypt foci) was demonstrated in the
azoxymethane-treated rat model19.
Collectively, these animal studies suggest that folate pos-
sesses dual modulatory effects on colo-rectal carcinogenesis
depending on the timing and dose of folate intervention.
Folate deficiency has an inhibitory effect whereas folate sup-
plementation may have a promoting effect on the progression
of established colo-rectal neoplasms. In contrast, folate
deficiency in normal colo-rectal mucosa appears to predispose
it to neoplastic transformation, and modest levels of folic acid
supplementation suppress, whereas supraphysiologic sup-
plemental doses enhance the development of cancer in
normal colo-rectal mucosa.
Folic acid in relation to DNA methylation and uracil
misincorporation
Epigenetic events including genomic hypomethylation and
aberrant hypermethylation of cytosine–guanine islands in
the promoter regions of a sub-set of genes appear important
in the development of human cancer20. Hypermethylation of
cytosine–guanine islands results in the silencing of gene
expression. Epigenetic alterations may play a central role in
establishing the conditions under which tumourigenesis can
become more likely, as epigenetic events in apparently
normal tissue are likely to be present long before neoplasms
are detectable21. Folate is required for the synthesis of S-ade-
nosylmethionine, the primary methyl group donor for DNA
methylation.
Thymidylate synthase converts deoxyuridine 50-monophos-
phate (dUMP) to deoxythymidine-50-monophosphate (dTMP)
for the provision of thymidine. Folate is required as a cofactor
for the reaction and deficiency can lead to uracil misincorpora-
tion associated with an increased risk of double-strand breaks
leading to chromosomal breaks and genomic instability22.
Thymidylate synthase is also a primary target for chemother-
apeutic agents, e.g. 5-fluorouracil. Nucleotide synthesis and
DNA methylation, therefore, provide relevant mechanisms
linking folate metabolism to colo-rectal carcinogenesis.
Professor John Mathers presented the results from an FSA-
funded trial of folic acid and riboflavin supplementation on colo-
nic mucosa DNA methylation and uracil misincorporation.
Three groups of volunteers were recruited to the study: individ-
uals with no evidence of neoplasia (n 95); patients with colonic
adenomatous polyps (n 102); and patients with CRC (n 74). At
baseline, blood samples and rectal mucosal biopsies were col-
lected, habitual diet was assessed and volunteers were geno-
typed for MTHFR 677C . T status. In a double-blind,
placebo-controlled intervention trial, normal subjects and
those with polyps received either placebo (n 48), 400mg folic
acid/d (n 49), 1200mg folic acid/d (n 53), or 400mg folic acid/
d plus 5mg riboflavin/d (n 54) for 50 d. A further set of blood
samples and mucosal biopsies was collected at the end of the
intervention period. At baseline, overall folate status was good
and there was the expected inverse relationship between
plasma folate and homocysteine. Mucosal folate concentration
was positively correlated with plasma folate concentration.
Methylation of the P16 gene promoter region increased signifi-
cantly with age and was higher in those with polyps and cancer
than in normal subjects. Folic acid supplementation produced
dose-dependent increases in plasma and mucosal folate concen-
trations and there were concomitant falls in plasma homocys-
teine concentration. Riboflavin supplementation increased
riboflavin status. Methylation specific PCR (MSP) detected
methylation in the promoter regions of the P16, HPP1, MLH1
and APC genes in 83–100% of volunteers. In contrast, only
3–12% of volunteers had detectable methylation of the DNA
repair gene MGMT. There were no significant effects of the
interventions on DNA methylation (genomic or gene-specific)
or on the misincorporation of uracil into DNA. The collection
of colo-rectal mucosal cells for biomarker analysis using a
‘brush biopsy’, whichwas safer for, andmore acceptable to, vol-
unteers, was shown to be possible. There was no evidence of
differences in response between normal subjects and those
with polyps. This apparent lack of effect in both subject
groups may be due to the relatively short intervention period
or to the good folate status of the volunteers pre-supplemen-
tation.
Dr Ellen Kampman presented results from a case–control
study and a human intervention trial examining the relation-
ship between gene promoter methylation and intake of folate
and folic acid respectively. Cytosine–guanine island methyl-
ation of APC, p14, P16, MLH1, MGMT and RASSF1A gene
promoter regions was determined by MSP. In the case–control
study analyses, patients with colorectal adenoma (n 149) and
controls (n 286) with folate intake in the upper (.212mg/d)
or lower (,183mg/d) tertile who were CC or TT homozygotes
were included. MSP was performed for patients only, using
paraffin-embedded colo-rectal adenoma tissue23. The percen-
tages of promoter methylation ranged from 15·7% to
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64·2%. Folate intake showed a non-significant inverse associ-
ation with promoter methylation in colo-rectal adenomas in
case–case comparisons, especially among those with the TT
genotype. This appeared to be most pronounced for MGMT.
The MTHFR 677C . T genotype alone was not associated
with promoter methylation.
In the intervention trial, uracil misincorporation assays and
MSP were performed on ‘normal’ rectal mucosa from eighty-
six subjects with a history of colo-rectal adenomas who were
randomly assigned to receive either a high dose of folic acid
(5mg/d) and vitamin B12 (1·25mg/d) or placebo for 6
months. Randomization was stratified for MTHFR 677C . T
genotype. MGMT gene promoter methylation was significantly
increased and uracil misincorporation and methylation of the
other gene promoter regions examined showed a non-signifi-
cant increase in the intervention group, which appeared to
be more pronounced in subjects with the TT genotype.
These studies suggest that dietary folate may be inversely
associated with MGMT promoter methylation in colo-rectal
adenomas, especially for those with the TT genotype, but
that a high dose of folic acid, in subjects with a recent history
of adenomas, may adversely affect DNA methylation (silen-
cing of the DNA repair gene, MGMT) and possibly DNA syn-
thesis (increased uracil misincorporation), especially among
TT homozygotes.
The application of microarray techniques to the measure-
ment of gene-specific methylation status potentially offers the
advantage of identifying in which genes methylation status is
altered in disease processes, e.g. CRC, and in response to
specific stimuli, e.g. diet. Professor Stephen Downes presented
the preliminary results from an FSA-funded project to develop
a methylation-sensitive microarray-based technique that could
screen many genes simultaneously for changes in methylation.
The technique employs standard gene expression cDNA
microarrays: the number of genes screened is limited to
the number of genes on the microarray. It involves cutting
genomic DNA with methylation-sensitive and, separately,
with methylation-insensitive, isoschizomers, adding linkers
that are then annealed to the DNA, and PCR amplifying
the products with primers at the linkers. DNA from the
different isoschizomer digestions are labelled with different
fluorochromes, and competitively hybridized to the array.
The greater the number of methylated sites in or adjacent to
any one gene, the weaker is the signal from the methylation-
sensitive digest.
Folate depletion and repletion studies with SW620 colon
tumour cells and the analysis of colon biopsy samples from
patients with high and low folate status, and from subjects
who participated in the trial presented by Professor John
Mathers described earlier, led to the identification of several
candidate genes, e.g. H1F0, whose methylation appeared to
be sensitive to folate status. These findings are preliminary
and validation with established techniques is ongoing.
Folic acid polyp recurrence trials
Professor Ken Muir presented results from the United King-
dom Colorectal Adenoma Prevention Consortium trial, in
which subjects with a recent history of adenomas were ran-
domly assigned to receive placebo (n 421) or 0·5mg folic
acid (n 432) daily with or without aspirin. The treatment
was for 3 years, after which subjects received a second
follow-up colonoscopy. Folic acid supplementation had no
effect on overall adenoma occurrence (relative risk (RR)
1·07, 95% CI 0·85, 1·34) nor on risk of advanced adenoma
occurrence (RR 0·98, 95% CI 0·68, 1·40). The effect of
folate metabolism genotypes on adenoma risk, in relation to
folic acid supplementation, was examined in a subset of sub-
jects (n 546). A significant reduction in recurrence risk was
observed in subjects heterozygous for the methionine synthase
reductase gene polymorphism (MTRR 66A . G) (RR 0·64,
95% CI 0·46, 0·90) who received folic acid supplements,
but not in those who did not receive folic acid; when homozy-
gous subjects were included in the analysis, however, there
was no significant effect24. No significant effect of folic acid
supplementation on adenoma risk was observed in subjects
analysed for other folate metabolism genotypes: MTHFR
677C . T, MTHFR 1298A . C, MTR 2756A . G, TSER,
TSER 3R G . C, and TS 1494del6.
Professor John Baron presented results from the North
American Aspirin–Folate Polyp Prevention Study, in
which subjects with a recent history of adenomas were ran-
domly assigned to receive placebo (n 505) or 1mg folic
acid (n 516) daily with or without aspirin. This trial was
conducted in the context of the folic acid fortification of
flour in North America, which is estimated to provide
about 200mg folic acid/d25. Initially designed with a 3-
year treatment and follow-up, subjects were offered the
option to continue randomized treatment for a second colo-
noscopic surveillance cycle (74% accepted extended treat-
ment). In the first surveillance cycle, adherence to study
medications and avoidance of folic-acid-containing vitamin
supplements was good, with compliance rates varying
over time between 87% and 96% of subjects. In the first
3 years, folic acid supplementation had no effect on overall
adenoma occurrence (RR 1·04, 95% CI 0·90, 1·20) and
showed a non-significant increase in the risk of advanced
(RR 1·32, 95% CI 0·90, 1·92) or multiple lesions (RR
1·20, 95% CI 0·80, 1·81). In the second follow-up interval,
the RR were higher. For all adenomas, the RR was 1·13
(95% CI 0·93, 1·37), for advanced lesions it was 1·67
(95% CI 1·00, 2·80) and for multiple adenomas it was
2·32 (95% CI 1·23, 4·35).
Folic acid supplementation at 1mg/d did not reduce the
incidence of colorectal adenomas in subjects with a recent his-
tory of adenomas. There was some evidence that folic acid
supplementation of 1mg/d may increase the risk of multiple
adenomas in these subjects, but this needs confirmation in
other studies.
There is ambiguity about how to interpret the suggestions of
increased risks during the second surveillance cycle. It could
be that more prolonged folic acid supplementation is required
for such an adverse effect, or that the original 3 years’ sup-
plementation was responsible for the increase, but it became
evident only after a latent period of 3 years.
Discussion
The functions of folate in nucleotide synthesis and DNA meth-
ylation are considered central to a possible role in carcinogen-
esis and provide mechanisms by which it could be involved in
both a beneficial and detrimental way26. Some animal studies
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suggest that folic acid supplementation may help prevent the
development of new cancers, but such studies also suggest
that folic acid supplementation may promote the progression
of existing premalignant/preneoplastic and neoplastic lesions.
Furthermore, chemotherapeutic agents, e.g. methotrexate and
5-fluorouracil, target folate metabolism. A crucial issue with
regard to this possible dual effect is the timing of exposure
and dose of folic acid used.
The results from human intervention studies investigating
an effect of folic acid supplementation on putative markers
for CRC risk, e.g. DNA methylation and uracil misincorpora-
tion, are inconclusive. Studies investigating an effect of folic
acid supplementation on global DNA methylation are compli-
cated by differences in the analytical methods used; further-
more, most widely used methods for assessing genomic
methylation provide no information on which cytosine resi-
dues within the genome are methylated and it is possible
that reported changes in global DNA methylation are weighted
towards changes within ‘junk’ DNA regions with no obvious
implications for genomic stability, gene expression or cell
function27.
In the trial presented by Professor John Mathers there was
no effect of folate supplementation on global DNA methyl-
ation in colo-rectal mucosa. In a previous trial in adenoma
patients, high-dose folic acid supplementation (5mg/d) for 6
months increased genomic DNA methylation in colonic muco-
sal biopsies, but when supplementation was continued for 12
months, genomic methylation was no different from that in
placebo-treated subjects28. A similar trial in adenoma patients
observed that, compared with placebo, folic acid supplemen-
tation (400mg/d) increased genomic DNA methylation in leu-
cocytes and non significantly in the colonic mucosa29. Other
studies have shown that a few weeks of moderate folate
depletion resulted in reduced global DNA methylation in cir-
culating leucocytes, but any effect of folate repletion was
inconsistent30–32.
In healthy subjects, no effect on leucocyte genomic DNA
methylation was observed after folic acid supplementation
(1·2mg/d for 10 weeks), but uracil misincorporation was
reduced with the effect being more pronounced in those
with lower erythrocyte folate concentration at baseline33.
The study presented by Professor John Mathers, however, pro-
vides no evidence that folic acid supplementation (up to
1·2mg/d for 50 d) alters colo-rectal mucosa uracil misincor-
poration. In contrast, results from the trial presented by Dr
Ellen Kampman suggest that high-dose folic acid supplemen-
tation (5mg/d for 6 months) may actually increase colo-rectal
mucosa uracil misincorporation in subjects with a recent his-
tory of adenomas. This finding needs confirmation in a
larger trial.
Two trials presented at the workshop assessed the effect of
folic acid supplementation on gene-specific DNA methylation
in the colo-rectal mucosa. While the trial presented by Pro-
fessor John Mathers observed no effect of folic acid sup-
plementation on DNA methylation in the genes examined
(including MGMT), the trial presented by Dr Ellen Kampman
showed high-dose folic acid supplementation to increase
MGMT methylation status. This may be an adverse effect
since MGMT methylation in the colo-rectal mucosa may
result in gene silencing34 and could represent a field effect pre-
disposing to CRC35.
The results from two polyp recurrence trials were presented
at the workshop, neither of which demonstrated a beneficial
effect on adenoma risk of folic acid supplementation (either
0·5mg or 1mg/d) over 3 years; however, in the North Amer-
ican trial the continued supplementation with 1mg/d for a
further 3–5 years was associated with an increased risk
for more advanced lesions and multiple adenomas, suggesting
folic acid supplementation may have promoted the progression
of premalignant lesions. The United Kingdom Colorectal
Adenoma Prevention Consortium trial provided no evidence
of any adverse effects of 0·5mg folic acid/d for 3 years on
adenoma risk.
Overall, human intervention trials to date do not support a
protective role of folic acid supplementation on CRC risk
and there is some evidence to suggest an adverse effect of
1mg/d or more when administered after colo-rectal neoplastic
lesions have been established.
It has been suggested that if folate promotes the progression
of preneoplastic lesions in human subjects, as demonstrated in
some animal models, then a trial of recurrent polyps in sub-
jects with a recent history of adenomas may be more relevant
to investigating possible deleterious effects of folate sup-
plementation26. Even conducting trials in adults without vis-
ible adenomas, however, raises the issue that many, perhaps
most, would have transformed foci by the time they are
middle-aged. This obviously raises ethical issues with regard
to future trials and highlights the need to address the possi-
bility that a key issue is the timing of exposure with respect
to carcinogenesis.
To date all intervention trials investigating the relationship
of folate to CRC risk have used the synthetic form of folate,
folic acid. In human subjects, the degree to which folic acid
is reduced and methylated in the mucosal epithelial cells to
5-methylenetetrahydrofolate remains unclear and dihydrofo-
late reductase activity appears to be more limited than in
rodents36. A dose of about 260mg has been reported to be
the threshold at which folic acid starts to appear in the
plasma postprandially37. There appears to be marked inter-
individual variation in this response and repeated adminis-
tration with smaller doses may result in the appearance of
unmetabolized folic acid in plasma postprandially38. The con-
centrations of unmetabolized folic acid observed in the blood
after the ingestion of supplements or fortified foods may have
different effects on folate-binding proteins and transporters
than naturally occurring folates37. Folic acid enters the one-
carbon cycles at a different point to 5- methylenetetrahydrofo-
late and could, therefore, have different effects26.
A cross-sectional study in the USA39, where supplement use
is common and the mandatory fortification of flour with folic
acid was introduced in 1998, detected unmetabolized folic
acid in fasting plasma samples of 78% of subjects (n 105).
The amount of unmetabolized folic acid in the plasma was
inversely associated with natural killer cell cytotoxicity, an
index of innate immune function and implicated in cancer
risk40.
Research recommendations
Future research should give consideration to the supplemental
form, as well as the timing and dose, of folate employed. The
inherent differences in folate absorption and metabolism
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between rodents and human subjects36 make it difficult to
extrapolate the animal data to human subjects and further
work is required to define dose–response effects. The further
investigation of metabolic genotypes, e.g. MTHFR 677C . T,
that may modulate the relationship between folate and CRC
risk was also highlighted at the workshop. The prognostic sig-
nificance of DNA methylation and uracil misincorporation for
CRC risk, as well as their relationship to diet, still need to be
determined.
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